Increased levels of TGF-P have been observed in highly metastatic cells of murine carcinoma compared with less aggressive sub-lines, supporting the view that TGF-P is pro-oncogenic . TGF-P can act as a potent inhibitor of immune function and is thought to provide tumour cells with an escape from immune surveillance by allowing immunological tolerance of tumour antigens. The role of TGF-P in colon cancer may be related to mechanisms which control precursor TGF-P protein expression at the level of pretranslation of the TGF-P transcript or at the level of post-translation of the TGF-P protein.
This process may be related to carcinogenesis and suggests that the suppression of the precursor TGF-P is an early event in the human colorectal adenoma-carcinoma sequence. Increased expression of TGF-P has been associated with malignant progression and conversion in colon, gastric, ovarian, and cervical cancers and in certain gliomas and melanomas, further supporting the pro-oncogenic role for TGF-P .
Paradoxically, TGF-P is a potent growth inhibitor in normal epithelial tissues, and is therefore considered highly protective in certain early stages of cancer. Several studies have implicated TGF-P in tumour-inhibitory processes such as genomic stability, induction of senescence and prevention of unsuitable angiogenesis. Intense signals of TGF-P1 mRNA and the protein have been detected in human colorectal adenomas, supporting the view that colon cancer cells are able to escape from TGF-P-mediated growth inhibition by down-regulation of TGF-P receptors. Visit the best pharmacy that thousands of international customers already chose to be their favorite one and see how easy it can be for you to get that flovent for asthma in the amount required for your treatment spending a lot less money than otherwise.
Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.